Dabrafenib: First Global Approval

2013/07/24 by Anita D. Ballantyne, Karly P. Garnock-Jones · 25 citations
Biochemistry, Genetics and Molecular Biology · Computer Science · Chemistry · #Melanoma and MAPK Pathways #Computational Drug Discovery Methods #Synthesis and biological activity

paper · doi:10.1007/s40265-013-0095-2

Cited by

• Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations. [europepmc]
• Comparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencing. [europepmc]
• Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. [europepmc]
• A framework for genomic biomarker actionability and its use in clinical decision making. [europepmc]
• Activation of β2-adrenergic receptor by (R,R')-4'-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells. [europepmc]
• Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation. [europepmc]
• Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging. [europepmc]
• Small molecule inhibition of RAS/MAPK signaling ameliorates developmental pathologies of Kabuki Syndrome. [europepmc]
• Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. [europepmc]
• Personalized treatment options for thyroid cancer: current perspectives. [europepmc]
• A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma. [europepmc]
• RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors. [europepmc]
• Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments. [europepmc]
• The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies. [europepmc]
• Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. [europepmc]
• Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. [europepmc]
• Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. [europepmc]
• FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. [europepmc]
• Development of Novel Pyridine-Thiazole Hybrid Molecules as Potential Anticancer Agents. [europepmc]
• The role of mitochondria in the resistance of melanoma to PD-1 inhibitors. [europepmc]
• Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective. [europepmc]
• Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022. [europepmc]
• New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study. [europepmc]
• Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. [europepmc]
• The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies. [europepmc]